← Back to Screener
Unicycive Therapeutics, Inc. Common Stock (UNCY)
Price$6.92
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-0.97%
Price vs S&P 500 (4W)-12.84%
VGM Score61.18
Market Capitalization$198.38M
All Metrics
Book Value / Share (Quarterly)$1.49
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.14
Price vs S&P 500 (YTD)11.77%
Net Profit Margin (TTM)-4159.11%
EPS (TTM)$-2.08
10-Day Avg Trading Volume0.88M
EPS Excl Extra (TTM)$-2.08
EPS (Annual)$-5.48
Dividend / Share (Annual)$0.15
ROI (Annual)-494.27%
Cash / Share (Quarterly)$2.16
ROA (Last FY)-115.98%
EBITD / Share (TTM)$-1.58
Operating Margin (TTM)-2931.41%
Cash Flow / Share (Annual)$-1.42
P/B Ratio5.26x
P/B Ratio (Quarterly)4.40x
Net Income / Employee (Annual)$-1,749,000
Net Interest Coverage (TTM)-1805.00x
ROA (TTM)-82.31%
EPS Incl Extra (Annual)$-5.48
Current Ratio (Annual)2.59x
Quick Ratio (Quarterly)2.06x
3-Month Avg Trading Volume0.59M
52-Week Price Return-10.01%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.10
P/S Ratio (Annual)293.90x
Asset Turnover (Annual)0.05x
52-Week High$11.00
EPS Excl Extra (Annual)$-5.48
26-Week Price Return6.96%
Quick Ratio (Annual)2.18x
13-Week Price Return1.32%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.40x
Enterprise Value$161.01M
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4525.04%
Cash / Share (Annual)$1.87
3-Month Return Std Dev61.46%
Net Income / Employee (TTM)$-1,902,300
ROE (Last FY)-494.27%
Net Interest Coverage (Annual)-9.30x
EPS Basic Excl Extra (Annual)$-5.48
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.08
ROI (TTM)-131.18%
P/S Ratio (TTM)31.15x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.03
Forward P/E1.78x
Price vs S&P 500 (52W)-34.38%
Year-to-Date Return19.93%
5-Day Price Return-8.95%
EPS Normalized (Annual)$-5.48
ROA (5Y Avg)-431.02%
Net Profit Margin (Annual)-4525.04%
Month-to-Date Return-6.23%
Cash Flow / Share (TTM)$-1.48
EBITD / Share (Annual)$-4.79
Operating Margin (Annual)-3077.63%
EPS Basic Excl Extra (TTM)$-2.08
P/TBV (Quarterly)6.12x
P/B Ratio (Annual)4.11x
Pretax Margin (TTM)-4159.11%
Book Value / Share (Annual)$1.37
Price vs S&P 500 (13W)-6.94%
Beta1.67x
Revenue / Share (TTM)$0.00
ROE (TTM)-131.18%
52-Week Low$3.71
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.54est. -0.49
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
UNCYUnicycive Therapeutics, Inc. Common Stock | — | — | B | $6.92 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Unicycive Therapeutics is a biotechnology company developing novel therapies for kidney diseases. Its lead programs include Renazorb, a phosphate-binding agent in development for hyperphosphatemia, and UNI-494, an investigational therapy in late preclinical development for acute kidney injury.